Dr. Camidge on Toxicities of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

Video

Ross Camidge, MD, PhD, discusses toxicities observed with sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer.

Ross Camidge, MD, PhD, director, the Thoracic Oncology Clinical and Clinical Research Programs, the University of Colorado Anschutz Medical Campus, discusses toxicities observed with sunvozertinib (DZD9008) in EGFR Exon 20–Mutated non–small cell lung cancer (NSCLC).

Sunvozertinib is being investigated as a second- or later-line treatment in patients with NSCLC whose tumors harbor EGFR exon 20 insertion mutations in the phase 2 WU-KONG6 trial (CTR20211009).

For EGFR inhibitors such as sunvozertinib, it is important to consider adverse effects (AEs), Camidge says. If AEs prevent patients from receiving the recommended dosage of sunvozertinib, it is difficult to maintain efficacy, Camidge explains. However, based on data from the WU-KONG6 trial presented at the 2022 ESMO Congress, AEs appeared to be manageable, Camidge says. Grade 3 or higher drug-related, treatment-emergent AEs of diarrhea and rash occurred in 7.3% and 2.8% of patients, respectively, Camidge continues.

Additionally, drug-related AEs led to dose reduction in 20.2% of patients who received sunvozertinib at 300 mg, Camidge explains. Overall, sunvozertinib appears to be well tolerated and efficacious, and longer-term follow-up will help determine how long that efficacy will last, Camidge concludes.

Related Videos
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
A panel of 5 experts on lung cancer